Eli Lilly and Company
NYSELLY short interest climbs 21% in one week to 1.19% of float, driven by short sellers rebuilding positions as stock digests recent pipeline gains.
A new long-form analysis for LLY this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumEli Lilly and Company has spent the week digesting the retatrutide data windfall, adding another 7.6% to close at $1,144.68 — and the Street is now visibly scrambling to keep its targets relevant. The analyst story has…
Snapshot as of 21 Jun 2026
Eli Lilly and Company has given back a sliver of its remarkable May recovery, closing at $1,064 on June 2 — down 1.7% on the day but virtually unchanged on the week, as fresh safety questions around newly launched…
Eli Lilly and Company enters the final days of May having added 4.2% on the week, closing at $1,064.74 — its highest level since early in the year — with a fresh analyst target raise from BofA arriving the same day to…
Eli Lilly and Company has extended its post-earnings recovery past the $1,021 mark, but options traders are quietly adding downside protection even as short sellers pull back — a divergence worth watching heading into…
Eli Lilly enters the back half of May with short sellers in full retreat, a wall of bullish analyst upgrades, and a stock that has clawed back to within striking distance of the $990 level — all while the broader…
LLY enters the week at $988.87, up 13.1% over five sessions — its sharpest weekly rally in recent memory — as a strong earnings beat on April 30 reset expectations and sent a wave of upward analyst revisions through…
Eli Lilly heads into its May 4 Q1 report with the stock surging back toward a consensus that still sees meaningful upside from current levels. The standout heading into the print is the price action. Lilly jumped…
Why this matters: Three distinct ORTEX data streams—short interest, cost to borrow, and options sentiment—have simultaneously shifted on LLY in the past week. The convergence comes six days before the pharmaceutical…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LLY — free to start on ORTEX.
Sign up for free →Open LLY on ORTEX